Inhibikase Therapeutics has named Scott Wasserman to its Board of Directors.

Oct 20, 2026, 5:41 PM ETNew bossRead the original at streetinsider.com

Neutral

Inhibikase added Scott Wasserman to its board as Dennis Berman resigned. Its clinical work continues, and the report names no change to the business, so the board turnover does not shift its outlook.

IKT · Inhibikase Therapeutics, Inc.

AI read · Neutral

The AI's read

A board change can matter if it shifts company decisions, but this report gives no details about Wasserman's experience or Berman's departure. Inhibikase also says its drug development continues, with no reported change to that work. That leaves no clear reason to read the change as helping or hurting the company.

Get alerts for IKT

Follow Inhibikase Therapeutics, Inc. (IKT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IKT

Free on the App Store and Google Play, or on the web.